ASCO 2016: Keane's Corner blog - Bladder Cancer.
Thomas Keane, Editor-in-Chief UroToday.com, discusses new treatment advances for patients with metastatic urothelial cancer. The standard of care for patients with locally advanced or metastatic urothelial cancer is currently cisplatin-based chemotherapy, which is the only therapy ever shown to improve survival in this setting. However, nearly half of patients diagnosed with this disease will not be eligible for cisplatin-based therapy due to poor renal function, performance status, or other medical problems, which render the therapy too toxic. For these patients, we commonly use carboplatin-based therapy, which is considered less toxic. However, it is less efficacious. Regardless, for the vast majority of patients, the cancer will progress despite this therapy. And, in the second-line setting, there are no approved treatments and survival is very poor. New treatment advances for this patient population have been being investigated. In May 2016 atezolizumab—branded Tecentriq, a new cancer immunotherapy was approved by the FDA.